Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II

Chest

Volumn 151, Issue 4, 2017, Pages 813-820

  Tashkin, Donald P ^a   Volkmann, Elizabeth R ^a   Tseng, Chi Hong ^a   Roth, Michael D ^a   Khanna, Dinesh ^b   Furst, Daniel E ^a   Clements, Philip J ^a   Theodore, Arthur ^c   Kafaja, Suzanne ^a   Kim, Grace Hyun ^a   Goldin, Jonathan ^a   Ariolla, Edgar ^a   Elashoff, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cough; health related quality of life; immunosuppressive therapy; interstitial lung disease; scleroderma

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGH SPECIFIC QUALITY OF LIFE; COUGHING; DIFFUSING CAPACITY FOR CARBON MOXIDE; DISEASE SEVERITY; DYSPNEA; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LEICESTER COUGH QUESTIONNAIRE; LUNG FUNCTION; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA RELATED INTERSTITIAL LUNG DISEASE; TREATMENT RESPONSE; VISUAL ANALOG SCALE; COMPLICATION; COUGH; FEMALE; LUNG DISEASES, INTERSTITIAL; LUNG FUNCTION TEST; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

COUGH; CYCLOPHOSPHAMIDE; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85017100759     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.11.052     Document Type: Article

References (17)

1. 1 Theodore, A.C., Tseng, C.-H., Li, N., Elashoff, R.M., Tashkin, D.P., Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease. Chest 142:3 (2012), 614–621.
2. 2 Tashkin, D.P., Elashoff, R., Clements, F.J., et al., Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:25 (2006), 2655–2666.
3. 3 Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:10 (2007), 1026–1034.
4. 4 Tashkin, D.P., Roth, M.D., Clements, P.J., et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomized controlled trial. Lancet Respir Med 4:9 (2016), 708–719.
5. 5 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheumatol 23:5 (1980), 581–590.
6. 6 Mahler, D.A., Ward, J., Fierro-Carrion, G., et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD 1:2 (2004), 1–8.
7. 7 Beretta, L., Santaniello, A., Lemos, A., Masciocchi, M., Scorza, R., Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related QoL in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology (Oxford) 46:2 (2007), 296–301.
8. 8 Birring, S.S., Prudon, B., Carr, A.J., et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 58:4 (2003), 339–343.
9. 9 Khanna, D., Hays, R.D., Maranian, P., Seibold, et al. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum 61:9 (2009), 1257–1263.
10. 10 Bae, S., Allanore, Y., Furst, D.E., et al. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol 31:2 suppl 76 (2013), 57–63.
11. 11 McCloskey, D.A., Patella, S.J., Seibold, J.R., Health Assessment Questionnaire (HAQ) in systemic sclerosis (SSc). Arthritis Care Res, 3, 1990, S12.
12. 12 Steen, V.D., Medsger, T.A. Jr., Health assessment questionnaire (HAQ) in demonstrating disability and organ system change in systemic sclerosis (SSc). Arthritis Rheum, 38, 1995, S176.
13. 13 McHorney, C.A., Ware, J.E., Raczek, A.E., The MOS 36-item sort form health survey (SF-36): psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:3 (1993), 247–263.
14. 14 Kim, H.J., Brown, M.S., Elashoff, R., et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 21:12 (2011), 2455–2465.
15. 15 Kim, H.G., Tashkin, D.P., Clements, P.J., et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 28:5 suppl 62 (2010), S26–S35.
16. 16 Hanacek, J., Davies, A., Widdicombe, J.G., et al. Influence of lung stretch receptors on the cough reflex in rabbits. Respiration 45:3 (1984), 161–168.
17. 17 Karlsson, J.A., The role of capsaicin-sensitive C-fibre afferent nerves in the cough reflex. Pulm Pharmacol 9:5-6 (1996), 315–321.